Background For patients with heart failure, there is an inverse relation between body mass index (BMI) and mortality, sometimes called the obesity-paradox. However, the relationship might be either U-or J-shaped and might differ between patients with reduced (HFrEF) or preserved left ventricular ejection fraction (HFpEF). We sought to investigate this further in a dose-response meta-analysis of published studies. Methods PubMed and Embase from June 1980 to April 2017 were searched for prospective cohort studies evaluating associations between BMI and all-cause mortality in patients with HFrEF (LVEF < 40%) or HFpEF (LVEF ≥ 50%). Summary estimated effect sizes were obtained by using a random-effects model. Potential non-linear relationships were evaluated by using random-effects restricted cubic spline models. Results Ten studies were identified that included 96,424 patients of whom 59,263 had HFpEF (mean age 68 years of whom 38% were women) and 37,161 had HFrEF (mean age 60 years of whom 17% were women). For patients with HFpEF, the summary hazard ratio (HR) for all-cause mortality was: 0.93 (95% CI 0.89-0.97) per 5 units increase in BMI (I 2 = 75.8%, p for heterogeneity = 0.01 and Begg's test, p = 1.0, Egger's test, p = 0.29) but the association was U-shaped (p for non-linearity < 0.01) with the nadir of risk at a BMI of 32-33 kg/m 2 . For patients with HFrEF, the summary HR for all-cause mortality was: 0.96 (95% CI 0.92-0.99) (I 2 = 95%, p for heterogeneity < 0.001 and Begg's test, p = 0.45, Egger's test, p = 0.01). The relationship was also U-shaped (p < 0.01), although 'flatter' than for HFpEF, with the nadir at a BMI of 33 kg/m 2 . Conclusions For patients with heart failure, the relation between BMI and mortality is U-shaped with a similar nadir of risk for HFpEF and HFrEF at a BMI of 32-33 kg/m 2 . Whether interventions that alter weight in either direction can alter risk is unknown.
Introduction
Many studies have shown that mild-to-moderate obesity is associated with a lower mortality amongst patients with heart failure: the so-called obesity-paradox [1] [2] [3] [4] [5] . The possible causes of the paradox are controversial. There is no doubt that BMI declines as heart failure (HF) becomes more severe: some believe that a low BMI simply reflects more advanced disease. Adherents of this view suggest that interventions to reduce a high BMI will benefit patients symptomatically and perhaps prognostically, by reducing proinflammatory visceral adiposity and perhaps haemodynamic stress as well as improving glycaemic control [6] . Others believe that a higher BMI may provide a metabolic reserve as disease progresses or even be intrinsically beneficial, in which case efforts should be made to increase rather than reduce BMI. Indeed, one of the great successes of heart failure therapy, beta-blockers, increases BMI [7] .
A recent study from the MAGGIC [8, 9] collaboration, based on individual patient data, reported that there was a U-shaped relationship between BMI and all-cause mortality both for patients with HFpEF and those with HFrEF with the nadir of risk at a BMI of 30-34.9 kg/m 2 . In order to investigate this observation further, we conducted a systematic review and dose-response meta-analysis to quantify and better understand the potential non-linear relation between BMI and prognosis in prospective cohort studies of patients with HFpEF and HFrEF.
Methods

Search strategy
The study was designed according to the Meta-analysis of Observational Studies in Epidemiology (MOOSE) Group and the PRISMA 2009 guidelines [10, 11] . We searched for all prospective cohort and other related studies that evaluated the associations between BMI and all-cause mortality in patients either with heart failure and a reduced (HFrEF; LVEF < 40%) or preserved left ventricular ejection fraction (HFpEF; LVEF ≥ 50%). Only studies with at least three categories of BMI were considered [12] . Studies [13] [14] [15] with patients with a mean left ventricular ejection fraction (LVEF) close to 45% were not included as the patients could not be reliably classified as having predominantly HFpEF or HFrEF. To reduce bias, only prospective cohort studies were included, including an individual patient-data metaanalysis [8] .
PubMed and Embase from June 1980 to April 2017 were searched evaluating associations between BMI and allcause mortality in patients with HFrEF or HFpEF. There were no language restrictions. Search terms included: HFpEF, HFrEF, HFnEF, reduced, normal or preserved EF, reduced, normal or preserved ejection fraction, BMI, body mass index, mortality and death. We also searched reference lists of the retrieved articles to identify other eligible studies. Two investigators independently reviewed all titles and abstracts from the search results to identify articles that met the inclusion criteria. Selected studies were compared, and disagreement was resolved by discussion and consensus. If any of the eligibility criteria were not met, the article was excluded. If results were incomplete or unclear, attempts were made to contact the study authors. Articles finally selected for review were checked to avoid inclusion of data published in duplicate. Relevant information was collected on baseline characteristics, such as age, sex, New York Heart Association (NYHA) functional classification, HF phenotype, heart rhythm at baseline, mean follow-up and events.
Statistical analysis
The hazard ratio (HR) with 95% confidence intervals for all-cause mortality in each baseline BMI category obtained from multivariable models for all studies was used as the effect size. A dose-response association between BMI and all-cause mortality was assessed by the methods described by Greenland and Longnecker [16] and Orsini [17] based on a generalized least squares regression model using STATA version 14.2. We assumed that the reference category was the lowest BMI category for each study. For studies in which the reference group was not the lowest category, we transformed it to the lowest category using the method proposed by Orsini [18] . We used the mid-point of the corresponding range of BMI as the exposure value. When upper and lower categories were open-ended, we used the width of the adjacent category to calculate an upper or lower bound.
For studies that did not report the number of person-years by BMI category, we used approximated values based on follow-up period, number of subjects provided and number of BMI categories. One study [19] reported results for peak oxygen uptake ≤ 14 and > 14 ml kg −1 min −1 separately; we combined the estimated hazard ratios using a fixed-effect model to obtain an overall estimate. A potential non-linear relationship between BMI and mortality was evaluated by modelling BMI dose with the use of restricted cubic splines with 4 knots at fixed centiles (5, 35, 65 and 95%) based on all categories of BMI for all studies, and examined by testing the hypothesis that the regression coefficients of the spline transformations were all equal to zero. We produced a dose-response curve with a re-scaled reference category of BMI of 23.8 kg/m 2 , which we took as a value within the normal weight range. Summary estimated effect sizes were obtained using a random-effects model based on each study calculated using the method of Orsini et al. [20] . Heterogeneity was assessed using Q test and I 2 statistics [21] . Forest plots were used to represent graphically the results generated from the random-effects meta-analysis. The pooled HR and the degree of heterogeneity are presented. Publication bias was minimized by comprehensive literature searching. In addition, Begg's test [22] and Egger's test [23] were used to investigate publication bias.
Results
The selection process and results are shown in Fig. 1 . Of 622 articles found by the initial search, 47 were retrieved for more detailed evaluation. Ten studies were identified with 96,424 patients, for whom the mean age was 64 years; 28% were women. The biggest study contained 47,866 patients [24] and the smallest study 446 patients [25] . Where NYHA class was reported, most patients were in class III or IV. One study included only women [26] and one study included predominantly (96%) men [3] .
Most studies were conducted in the United States of America (Table 1) . Patients with a higher BMI were more likely to have a history of diabetes and hypertension, especially for patients with HFpEF. Patients with a BMI in the normal range were more likely to have IHD (Table 2) . Patients with HFrEF were more likely to take digoxin (Table 3) . Of the ten studies, nine reported all-cause mortality, three reported cardiovascular (CV) mortality and one reported death/urgent heart transplant/or ventricular assist device [19] . Duplicates removed N= 185 
HFpEF
Four studies [3, 8, 24, 27] including one individual patient data meta-analysis [8] included 59,263 patients of whom 6061 died. The average patient age was 68 years, and 38% were women. In multivariable analysis, the variables most commonly adjusted for were: age, sex, LVEF, diabetes, blood pressure, NYHA class, ischaemic aetiology and hypertension (Table 4 ). The summary HR per 5 unit increment in BMI was 0.93 (95% CI 0.89-0.97) [I 2 = 75.8%, p for heterogeneity = 0.01 ( Fig. 2a)] , with an inverse association between BMI and all-cause mortality. There was no evidence of publication bias (Begg's test, p = 1.0 or Egger's test, p = 0.29). The dose-response metaanalysis showed a U-shaped association between BMI and all-cause mortality with the lowest mortality at a BMI of 32-33 kg/m 2 (p < 0.01 for non-linearity, Fig. 3a) . Similar results were found when the MAGGIC meta-analysis [8] was excluded (leaving n = 53,210 patients). There were too few studies to investigate an interaction between age and mortality for patients with HFpEF (Table 5) .
HFrEF
Seven studies were identified [8, 19, 25, 26, [28] [29] [30] with 37,161 patients of whom 12,429 died. The average patient age was 60 years and 17% were women. In multivariable analysis, the variables most commonly adjusted for were: age, sex, LVEF, diabetes, blood pressure, NYHA class, ischaemic aetiology and hypertension (Table 4 ). The summary HR per 5 unit increment in BMI was 0.96 (95% CI 0.92-0.99) [I 2 = 95%, p for heterogeneity < 0.001 (Fig. 2b) ]. There was no evidence of publication bias (Begg's test, p = 0.45, Egger's test, p = 0.01). The dose-response meta-analysis showed a 'flatter' U-shaped association than for HFpEF with the lowest mortality at a BMI of 32 kg/m 2 (p < 0.01) (Fig. 3b) . Similar results were found excluding the MAGGIC meta-analysis [8] (Table 5) . One study [30] showed a negative relation between BMI and CV deaths in patients with HFrEF without giving detailed data. Another study [28] provided detailed data, and found a 'flatter' U-sharped relation between BMI and CV deaths than between BMI and all-cause mortality amongst patients with HFrEF (Table 2) . IHD ischaemic heart disease, HFpEF heart failure with preserved ejection fraction, HFrEF heart failure with reduced ejection fraction, HR hazard ratio Table 2 ( 
Discussion
This analysis confirms, in part, the existence of an obesityparadox for patients with heart failure. However, rather than a linear relationship between greater BMI and longevity, we observed, as anticipated, a U-shaped relationship; very low body weight and extreme obesity are both known to be dangerous. Previous studies have reported a U-shaped relationship between BMI and mortality with a nadir anywhere between 30 kg/m 2 [26] and 42 kg/m 2 [31] . Our analysis provides a considerably narrower range for the nadir of risk both for HFpEF and HFrEF at a BMI of 32-33 kg/m 2 although the U-shaped relationship was 'flatter' for HFrEF.
There are many possible explanations for the 'obesityparadox' in patients with heart failure. Obesity may be a risk factor for developing heart failure at an earlier age; younger patients generally have a better prognosis [32] [33] [34] [35] . Thus, so-called "reverse-causation" could account for the relationship between obesity and prognosis. Obesity might induce symptoms, such as breathlessness on exertion or lying down, leading to earlier diagnosis of heart failure or even misdiagnosis. Obesity might indicate less advanced disease. Weight loss is an ominous sign in patients with heart failure even before patients become notably cachectic [35] [36] [37] . A recent report [38] suggested that patients with heart failure and a greater waist-hip ratio had a worse prognosis. This may reflect the pro-inflammatory response to accumulation of visceral/omental fat. Obesity is also associated with the development of type 2 diabetes that is associated with an adverse prognosis in patients with heart failure. The proportion of patients with diabetes increases with BMI regardless of HF phenotype in all studies.
Alternatively, obesity might be protective. Fat might provide an energy reserve that helps a patient cope with the metabolic costs of illness, protecting muscle and bone from the catabolic effects of worsening heart failure. Fat might also provide protection against endotoxins [8, [39] [40] [41] [42] [43] [44] [45] . Treatment with beta-blockers causes BMI to rise and improves the prognosis of patients with HFrEF, although it is unclear whether this relationship is causal. However, ESC guidelines on heart failure no longer advise weight loss in moderately obese in patients [46] .
Many reports suggest an obesity-paradox for patients aged > 50 years with established cardio-metabolic disease. This is true for hypertension [47] , type-2 diabetes mellitus [48, 49] , atrial fibrillation [50, 51] and ischaemic heart disease [52] as well as heart failure [53] [54] [55] . Reversecausation could explain each instance. On the other hand, from a clinical perspective it is the prognosis of the patient who they are caring for that is important rather than the patient's prior medical history, which cannot be altered.
IHD ischaemic heart disease, HFpEF heart failure with preserved ejection fraction, HFrEF heart failure with reduced ejection fraction. '-' did not report Table 4 Hazard and odds ratios for all-cause mortality by BMI category for the included studies Association class; history of myocardial infarction; dyspnea; duration of HF symptoms; diabetes; hypertension; HF aetiology; blood pressure; heart rate; rales; elevated jugular venous pressure; peripheral oedema HFpEF heart failure with preserved ejection fraction, HFrEF heart failure with reduced ejection fraction Accordingly, knowing that a patient with heart failure who is slightly obese has a better prognosis might be helpful for making decisions about management. Patients might be advised to lose weight (and take more exercise) to improve symptoms and exercise capacity, but whether this will have a beneficial or deleterious effect on longevity is unknown. This is the first study using a dose-response meta-analysis to evaluate the association between BMI and all-cause mortality in patients with HFrEF and HFpEF. The advantage of using the method is that it provides estimates that better quantify the potential non-linear relation between BMI and all-cause mortality. Another advantage of the approach is that it does not require the use of the same cut points for BMI in all studies, which means that all the BMI data can be used.
One problem in interpreting the data is the definition of HFpEF. Many people have "abnormal" features of diastolic function in association with increasing age and obesity. In the absence of conclusive evidence of cardiac dysfunction (such as atrial dilatation or raised plasma concentrations of natriuretic peptides), the diagnosis of heart failure is in doubt. Amongst the studies of HFpEF that we have included, only one (Haass et al. [27] ) reported plasma concentrations of natriuretic peptides which, although raised, were much diabetes, blood pressure, NYHA class, ischemic aetiology and hypertension. We only included studies with BMI given in more than 2 categories, which potentially limits the number of studies. However, it makes more efficient for dose-response meta-analysis. In addition, weight changes in patients with heart failure, but the data are not available from the studies included in our meta-analysis to investigate the relation between weight change and outcome.
The relation between BMI and outcome might depend on the end-point chosen. Patients with HFpEF are more likely to die from non-cardiovascular causes than are patients with HFrEF [57] , but cause-specific mortality data were not available. Furthermore, no data are available to allow us to explore the effect of inflammation or dysglycaemia on the relation between BMI and survival.
Conclusion
Both for patients with HFpEF and HFrEF, the relationships between BMI and mortality are U-shaped with a similar nadir of risk at a BMI of 32-33 kg/m 2 . Whether interventions to change BMI alter risk is unknown. Further research is required to discover the reasons underlying the obesityparadox in heart failure and other cardio-metabolic diseases and to provide guidance on whether and how patients should attempt to lose or gain weight. 
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